Cat. No.: HY-16478

Trifluridine/tipiracil hydrochloride mixture

(Synonyms: TAS-102; FTD/TPI)

4 Cited Publications

고객리뷰

Based on 4 publication(s) in Google Scholar

Trifluridine/tipiracil hydrochloride mixture (TAS-102) is a potent and orally active nucleoside antitumor agent. The composition of Trifluridine/tipiracil hydrochloride mixture (TAS-102) is a 1:0.5 mixture (on a molar basis) of alpha,alpha,alpha-tri-fluorothymidine (FTD) and thymidine phosphorylase inhibitor (TPI). Trifluridine/tipiracil hydrochloride mixture (TAS-102) shows the antitumor activity mainly via the inhibition of thymidylate synthase (TS) and incorporation into DNA.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.96%
CAS No.: 733030-01-8
화학식: C₁₀H₁₁F₃N₂O₅.1/2C₉H₁₁ClN₄O₂.1/2HCl
분자량:435.76

보관:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Trifluridine/tipiracil hydrochloride mixture Chemical Structure

CAS No.: 733030-01-8

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- In Vivo
- Clinical Trial
Chemical Information
Publications (4)
용액&용해도
- In Vitro
- In Vivo
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

In Vivo

Trifluridine/tipiracil hydrochloride mixture (150 mg/kg/day; p.o.; twice a day for 14 days) prevents body weight loss and reduces the relative tumor volume in colorectal cancer and gastric cancer mice models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male nude mice bearing KM12C, KM12C/5-FU, DLD-1, DLD-1/5-FU, and SC-2 cells^[2]
Dosage:

150 mg/kg/day
Administration:

p.o.; twice a day for 14 days
Result:

Prevented body weight loss and reduced the relative tumor volume in colorectal cancer and gastric cancer mice models.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 733030-01-8
Appearance Solid
분자량 435.76
화학식 C₁₀H₁₁F₃N₂O₅.1/2C₉H₁₁ClN₄O₂.1/2HCl
Color White to off-white
SMILES

O=C1N([C@H]2C[C@H](O)[C@@H](CO)O2)C=C(C(F)(F)F)C(N1)=O.O=C3NC(CN4CCCC4=N)=C(Cl)C(N3)=O.[1/2].Cl
Synonyms

TAS-102; FTD/TPI
선적

Room temperature in continental US; may vary elsewhere.
보관

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (4)

All Cell Proliferation/Viability AssayIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Transl Oncol

A CEBPB/TYMP/GDF15 signaling axis mediates tumor growth and cisplatin resistance in bladder cancer. [Abstract]

2025 Nov:61:102537. PMID: 40957398

Trifluridine/tipiracil hydrochloride mixture purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 Nov:61:102537. [Abstract]

Cell viability of UMUC3 cells treated with Trifluridine/tipiracil hydrochloride mixture (TAS-102, 20 μM) or DMSO.

Trifluridine/tipiracil hydrochloride mixture purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 Nov:61:102537. [Abstract]

In vivo tumor growth in C57BL/6 mice bearing MB49 xenografts treated with PBS, cisplatin, Trifluridine/tipiracil hydrochloride mixture (TAS-102, 20 mg/kg, ip, twice a week), or both (C + T); representative tumor images are shown.

Trifluridine/tipiracil hydrochloride mixture purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 Nov:61:102537. [Abstract]

In vivo tumor growth in C57BL/6 mice bearing MB49 xenografts treated with PBS, cisplatin, Trifluridine/tipiracil hydrochloride mixture (TAS-102, 20 mg/kg, ip, twice a week), or both (C + T); representative tumor weight are shown.

Trifluridine/tipiracil hydrochloride mixture purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 Nov:61:102537. [Abstract]

In vivo tumor growth in C57BL/6 mice bearing MB49 xenografts treated with PBS, cisplatin, Trifluridine/tipiracil hydrochloride mixture (TAS-102, 20 mg/kg, ip, twice a week), or both (C + T); representative tumor volume are shown.
Am J Cancer Res

TAS-102 has a tumoricidal activity in multiple myeloma. [Abstract]

2020 Nov 1;10(11):3752-3764. PMID: 33294265
medRxiv

2026 Apr 18.
bioRxiv

BOGO: A Proteome-Wide Gene Overexpression Platform for Discovering Rational Cancer Combination Therapies. [Abstract]

2025 Sep 7:2025.09.02.673780. PMID: 40950237

용액&용해도

In Vitro:

H₂O : 100 mg/mL (229.48 mM; Need ultrasonic)

DMSO : 50 mg/mL (114.74 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

DMF : 20 mg/mL (45.90 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2948 mL

11.4742 mL

22.9484 mL

5 mM

0.4590 mL

2.2948 mL

4.5897 mL

10 mM

0.2295 mL

1.1474 mL

2.2948 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 50 mg/mL (114.74 mM); Clear solution; Need ultrasonic

Protocol 2

Add each solvent one by one: Saline

Solubility: 100 mg/mL (229.48 mM); Clear solution; Need ultrasonic

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Emura T, et al. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med. 2004;13(4):545-549. [Content Brief]

[2]. Nukatsuka M, et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts. Anticancer Res. 2015;35(3):1437-1445. [Content Brief]

[3]. Limagne E, Thibaudin M, Nuttin L, et al. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. Cancer Immunol Res. 2019;7(12):1958-1969. [Content Brief]

[4]. Suzuki N, Nakagawa F, Takechi T. Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer [published correction appears in Oncol Lett. 2021 Jul;22(1):511]. Oncol Lett. 2017;14(1):639-646. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMF / DMSO / H₂O	1 mM	2.2948 mL	11.4742 mL	22.9484 mL	57.3710 mL
	5 mM	0.4590 mL	2.2948 mL	4.5897 mL	11.4742 mL
	10 mM	0.2295 mL	1.1474 mL	2.2948 mL	5.7371 mL
	15 mM	0.1530 mL	0.7649 mL	1.5299 mL	3.8247 mL
	20 mM	0.1147 mL	0.5737 mL	1.1474 mL	2.8686 mL
	25 mM	0.0918 mL	0.4590 mL	0.9179 mL	2.2948 mL
	30 mM	0.0765 mL	0.3825 mL	0.7649 mL	1.9124 mL
	40 mM	0.0574 mL	0.2869 mL	0.5737 mL	1.4343 mL
DMSO / H₂O	50 mM	0.0459 mL	0.2295 mL	0.4590 mL	1.1474 mL
	60 mM	0.0382 mL	0.1912 mL	0.3825 mL	0.9562 mL
	80 mM	0.0287 mL	0.1434 mL	0.2869 mL	0.7171 mL
	100 mM	0.0229 mL	0.1147 mL	0.2295 mL	0.5737 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Trifluridine/tipiracil hydrochloride mixture

4 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Trifluridine/tipiracil hydrochloride mixture

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Anti-COVID-19 Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Heterocyclic Compound Library

Off-patent Drug Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Trifluridine/tipiracil hydrochloride mixture

Biological Activity

Chemical Information

Publications (4)

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Trifluridine/tipiracil hydrochloride mixture

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Anti-COVID-19 Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Heterocyclic Compound Library

Off-patent Drug Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Trifluridine/tipiracil hydrochloride mixture

Biological Activity

Chemical Information

Publications (4)

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Trifluridine/tipiracil hydrochloride mixture Related Classifications

HY-16478 Related Classifications